Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir

Table 2 Summary of efficacy results from real-life studies of entecavir in nucleos(t)ide analogue-naïve patients n (%)[21]

Study	Median follow-up (range)	Patients(n)	Cut-off (assaylimit) (IU/mL)	HBV DNA undetectable1	HBeAg seroconversion12	HBsAg loss1
ORIENTE[22]	52 wk (46-53 wk)	190	50	115 (82)	12 (21)	2 (1)
VIRGIL[23]	19 mo (3-45 mo)	243	80	126 (74)	13 (15)	3 (1)
King’s College cohort[24]	28 mo (NR)	154	12	NR	NR	NR
Italian cohort[25]	58 mo (2-80 mo)	418	12	93 (99)	527 (31 patients)	337 (15 patients)
Argentinean cohort[29]	181 wk (108-248 wk)	169	6	34 (100)	71 (68)	23 (14)
Hong Kong cohort[32]	3 yr (12-60 mo)	222	12	51 (90)	16 (53)	1 (0.5)3
Japan cohort[33]	2.37 yr (0.5-7.2 yr)	473	12	70 (96)	93 (42)	1 (0.2)
China cohort[34]	27.5 mo (3-73 mo)	230	100	NR	17 (15)	1 (0.4)
China cohort 2[35]	191 wk (1-233 wk)	1768	50	1327 (83)	NR	NR
Taiwan cohort[36]	144 wk	98	NR	93 (95)	5 (12)	0
Taiwan cohort 2[37]	25.3 mo (12-69 mo)	248	6	33 (82)	64 (28)	NR
United States cohort[38]	25 mo (6-68 mo)	169	100	75 (44)	12 (8)	NR
United States cohort 2[39]	36 mo	136	100	115 (85)	41 (30)	0
Australia cohort[40]	26 mo (3-46)	163	12	134 (82)	66 (43)	1 (0.6)

¹Unless otherwise specified;

²Median (interquartile range);

³Advanced fibrosis in 34%.